AFG
CPRX icon

Albion Financial Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Albion Financial Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-24,800
Closed -$18K – 192
2016
Q2 		$18K Buy
+24,800
New +$20K ﹤0.01% 182

Other funds holding CPRX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
TCM
Tanaka Capital Management New York $59.9M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Albion Financial Group's CPRX Position: Q3 2016 in Review

Albion Financial Group sold out of Catalyst Pharmaceutical (CPRX) in Q3 2016, closing a stake of 24,800 shares — an estimated $18K sold.

Albion Financial Group first reported a position in CPRX in Q2 2016 and held it in 1 quarter. The position peaked at $18K in Q2 2016. 49 funds tracked by Wall St. Rank hold CPRX as of Q3 2016.

  • Albion Financial Group reported no remaining Catalyst Pharmaceutical position as of Q3 2016 after selling out during the quarter.
  • Albion Financial Group sold 24,800 Catalyst Pharmaceutical shares in Q3 2016, an estimated $18K.
  • Albion Financial Group first reported a position in Catalyst Pharmaceutical in Q2 2016 and held it in 1 quarter.
  • Albion Financial Group's Catalyst Pharmaceutical position peaked at $18K in Q2 2016.
  • 49 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2016.

Based on Albion Financial Group's 13F filing for Q3 2016, filed 3 Nov 2016.